The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity
Open accessAbstract
// Keith O’Brien 1, * , Michelle C. Lowry 1, * , Claire Corcoran 1 , Vanesa G. Martinez 1 , Melissa Daly 1 , Sweta Rani 1 , William M. Gallagher 2 , Marek W. Radomski 1 , Roderick A.F. MacLeod 3 , Lorraine O’Driscoll 1 1 School of Pharmacy and Pharmaceutical Sciences & Trinity Biomedical Sciences Institute, Trinity College, Dublin, Ireland 2 Cancer Biology and Therapeutics Laboratory, Conway Institute, UCD School of Biomolecular and Biomedical Science, Dublin, Ireland 3 Leibniz Institute DSMZ, German Collection of Human and Animal Cell Cultures, Braunschweig, Germany * These authors have contributed equally to this work Correspondence to: Lorraine O’Driscoll, e-mail: lodrisc@tcd.ie Keywords: exosomes/extracellular vesicles, miRNAs, breast cancer Received: October 06, 2014 Accepted: September 14, 2015 Published: September 24, 2015 ABSTRACT Exosomes (EVs) have relevance in cell-to-cell communication carrying pro-tumorigenic factors that participate in oncogenesis and drug resistance and are proposed to have potential as self-delivery systems. Advancing on our studies of EVs in triple-negative breast cancer, here we more comprehensively analysed isogenic cell line variants and their EV populations, tissues cell line variants and their EV populations, as well as breast tumour and normal tissues. Profiling 384 miRNAs showed EV miRNA content to be highly representative of their cells of origin. miRNAs most substantially down-regulated in aggressive cells and their EVs originated from 14q32. Analysis of miR-134, the most substantially down-regulated miRNA, supported its clinical relevance in breast tumours compared to matched normal breast tissue. Functional studies indicated that miR-134 controls STAT5B which, in turn, controls Hsp90. miR-134 delivered by direct transfection into Hs578Ts(i) 8 cells (in which it was greatly down-regulated) reduced STAT5B, Hsp90, and Bcl-2 levels, reduced cellular proliferation, and enhanced cisplatin-induced apoptosis. Delivery via miR-134-enriched EVs also reduced STAT5B and Hsp90, reduced cellular migration and invasion, and enhanced sensitivity to anti-Hsp90 drugs. While the differing effects achieved by transfection or EV delivery are likely to be, at least partly, due to specific amounts of miR-134 delivered by these routes, these EV-based studies identified miRNA-134 as a potential biomarker and therapeutic for breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer
Taylor, D. D., & Gercel-Taylor, C. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.04.033 · Cited by 2,288
RetractedValadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. (2007) · Nature Cell Biology · doi:10.1038/ncb1596 · Cited by 12,834
NCBI GEO: archive for functional genomics data sets—update
Barrett, T., Wilhite, S. E., Ledoux, P., Evangelista, C., Kim, I. F., Tomashevsky, M., Marshall, K. A., Phillippy, K. H., Sherman, P. M., Holko, M., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1193 · Cited by 10,418
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers
Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., Negrini, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307323101 · Cited by 4,095
MicroRNA Targeting Specificity in Mammals: Determinants beyond Seed Pairing
Grimson, A., Farh, K. K.-H., Johnston, W. K., Garrett-Engele, P., Lim, L. P., & Bartel, D. P. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.017 · Cited by 3,766
Characterization of extracellular circulating microRNA
Turchinovich, A., Weiz, L., Langheinz, A., & Burwinkel, B. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr254 · Cited by 1,941
The evolution of gene regulation by transcription factors and microRNAs
Chen, K., & Rajewsky, N. (2007) · Nature Reviews Genetics · doi:10.1038/nrg1990 · Cited by 1,547
MicroRNA-Cancer Connection: The Beginning of a New Tale
Calin, G. A., & Croce, C. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0800 · Cited by 1,053
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szallasi, Z., Li, Q., Juul, N., Leong, C.-O., Calogrias, D., Buraimoh, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4725 · Cited by 981
Lin, N. U., Claus, E., Sohl, J., Razzak, A. R., Arnaout, A., & Winer, E. P. (2008) · Cancer · doi:10.1002/cncr.23930 · Cited by 727
Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer
Anders, C. K., & Carey, L. A. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.s.008 · Cited by 625
Pattern of metastatic spread in triple-negative breast cancer
Dent, R., Hanna, W. M., Trudeau, M., Rawlinson, E., Sun, P., & Narod, S. A. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0086-2 · Cited by 554
WORKMAN, P., BURROWS, F., NECKERS, L., & ROSEN, N. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1391.012 · Cited by 521
A Large Imprinted microRNA Gene Cluster at the Mouse Dlk1-Gtl2 Domain
Seitz, H., Royo, H., Bortolin, M.-L., Lin, S.-P., Ferguson-Smith, A. C., & Cavaillé, J. (2004) · Genome Research · doi:10.1101/gr.2743304 · Cited by 515
Extracellular vesicles as drug delivery systems: Lessons from the liposome field
van der Meel, R., Fens, M. H. A. M., Vader, P., van Solinge, W. W., Eniola-Adefeso, O., & Schiffelers, R. M. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.07.049 · Cited by 482
Lowery, A. J., Miller, N., Devaney, A., McNeill, R. E., Davoren, P. A., Lemetre, C., Benes, V., Schmidt, S., Blake, J., Ball, G., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2257 · Cited by 450
Corcoran, C., Rani, S., O’Brien, K., O’Neill, A., Prencipe, M., Sheikh, R., Webb, G., McDermott, R., Watson, W., Crown, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050999 · Cited by 448
Self-citationLeukemia cell to endothelial cell communication via exosomal miRNAs
Umezu, T., Ohyashiki, K., Kuroda, M., & Ohyashiki, J. H. (2013) · Oncogene · doi:10.1038/onc.2012.295 · Cited by 448
Tanaka, Y., Kamohara, H., Kinoshita, K., Kurashige, J., Ishimoto, T., Iwatsuki, M., Watanabe, M., & Baba, H. (2013) · Cancer · doi:10.1002/cncr.27895 · Cited by 446
André, F., & Zielinski, C. C. (2012) · Annals of Oncology · doi:10.1093/annonc/mds195 · Cited by 329
Caldas-Lopes, E., Cerchietti, L., Ahn, J. H., Clement, C. C., Robles, A. I., Rodina, A., Moulick, K., Taldone, T., Gozman, A., Guo, Y., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903392106 · Cited by 315
Identifying mRNA, MicroRNA and Protein Profiles of Melanoma Exosomes
Xiao, D., Ohlendorf, J., Chen, Y., Taylor, D. D., Rai, S. N., Waigel, S., Zacharias, W., Hao, H., & McMasters, K. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046874 · Cited by 277
Exosomes as nano-theranostic delivery platforms for gene therapy
Tan, A., Rajadas, J., & Seifalian, A. M. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.06.014 · Cited by 242
O’Brien, K., Rani, S., Corcoran, C., Wallace, R., Hughes, L., Friel, A. M., McDonnell, S., Crown, J., Radomski, M. W., & O’Driscoll, L. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.01.017 · Cited by 239
Self-citationIntracellular and Extracellular MicroRNAs in Breast Cancer
Corcoran, C., Friel, A. M., Duffy, M. J., Crown, J., & O'Driscoll, L. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.150730 · Cited by 225
Self-citationCorcoran, C., Rani, S., & O'Driscoll, L. (2014) · The Prostate · doi:10.1002/pros.22848 · Cited by 223
Self-citationIntegrated MicroRNA and mRNA Signatures Associated with Survival in Triple Negative Breast Cancer
Cascione, L., Gasparini, P., Lovat, F., Carasi, S., Pulvirenti, A., Ferro, A., Alder, H., He, G., Vecchione, A., Croce, C. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055910 · Cited by 179
Functional transfer of microRNA by exosomes
Stoorvogel, W. (2012) · Blood · doi:10.1182/blood-2011-11-389478 · Cited by 174
Zhang, J.-P., Zeng, C., Xu, L., Gong, J., Fang, J.-H., & Zhuang, S.-M. (2014) · Oncogene · doi:10.1038/onc.2013.369 · Cited by 160
Ratio of miR-196s to HOXC8 Messenger RNA Correlates with Breast Cancer Cell Migration and Metastasis
Li, Y., Zhang, M., Chen, H., Dong, Z., Ganapathy, V., Thangaraju, M., & Huang, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1675 · Cited by 157
Cimino, D., Pittà, C. D., Orso, F., Zampini, M., Casara, S., Penna, E., Quaglino, E., Forni, M., Damasco, C., Pinatel, E., et al. (2012) · The FASEB Journal · doi:10.1096/fj.12-214692 · Cited by 154
Hollingshead, M. G., Alley, M. C., Burger, A. M., Borgel, S. D., Pacula-Cox, C. M., Fiebig, H., & Sausville, E. A. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0939-2 · Cited by 153
Eiseman, J. L., Lan, J. Q., Lagattuta, T. F., Hamburger, D. R., Joseph, E., Covey, J. M., & Egorin, M. J. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0865-3 · Cited by 152
Kerangueven, F., Noguchi, T., Coulier, F., Allione, F., Wargniez, V., Simony-Lafontaine, J., Longy, M., Jacquemier, J. D., Sobol, H., Eisinger, F., et al. (1997) · PubMed · Cited by 151
Münster, P. N., Srethapakdi, M., Moasser, M. M., & Rosen, N. X. (2001) · PubMed · Cited by 145
Singh, R., & Saini, N. (2012) · Journal of Cell Science · doi:10.1242/jcs.095976 · Cited by 135
Li, J., Wang, Y., Luo, J., Fu, Z., Ying, J., Yu, Y., & Yu, W. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.09.016 · Cited by 134
Bray, I. M., Bryan, K. R., Prenter, S., Buckley, P. G., Foley, N. H., Murphy, D. M., Alcock, L., Mestdagh, P., Vandesompele, J., Speleman, F., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007850 · Cited by 123
Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer
Roy, S. S., Gonugunta, V. K., Bandyopadhyay, A. M., Rao, M. K., Goodall, G. J., Sun, L., TEKMAL, R. R., & Vadlamudi, R. (2013) · Oncogene · doi:10.1038/onc.2013.332 · Cited by 115
Haller, F., von Heydebreck, A., Zhang, J. D., Gunawan, B., Langer, C., Ramadori, G. P., Wiemann, S., & Şahin, Ö. (2009) · The Journal of Pathology · doi:10.1002/path.2610 · Cited by 113
Novel suppressor loci on chromosome 14q in primary bladder cancer.
Chang, W. Y., Cairns, P., Schoenberg, M., Polascik, T. J., & Sidransky, D. (1995) · PubMed · Cited by 105
Expression of miR-487b and miR-410 encoded by 14q32.31 locus is a prognostic marker in neuroblastoma
Gattolliat, C.-H., Thomas, L., Ciafrè, S. A., Meurice, G., Teuff, G. L., Job, B., Richon, C., Combaret, V., Dessen, P., Valteau‐Couanet, D., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.388 · Cited by 99
Gallerne, C., Prola, A., & Lemaire, C. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.02.014 · Cited by 97
miR‐10b*, a master inhibitor of the cell cycle, is down‐regulated in human breast tumours
Biagioni, F., Moshe, N. B. B., Fontemaggi, G., Canu, V., Mori, F., Antoniani, B., Benedetto, A. D., Santoro, R., Germoni, S., Angelis, F. D., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201483 · Cited by 96
MicroRNAs at the human 14q32 locus have prognostic significance in osteosarcoma
Sarver, A. L., Thayanithy, V., Scott, M. C., Cleton-Jansen, A., Hogendoorn, P. C. W., Modiano, J. F., & Subramanian, S. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-7 · Cited by 95
Triple-negative breast cancer: are we making headway at least?
Arnedos, M., Bihan, C., Delaloge, S., & André, F. (2012) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012444711 · Cited by 90
Yin, C., Wang, P., Xu, W., Yang, Y., Zhang, Q. H., Ning, B., Zhang, P.-P., Zhou, W., Xie, W., Chen, W., et al. (2013) · Hepatology · doi:10.1002/hep.26573 · Cited by 81
Hughes, L., Malone, C., Chumsri, S., Burger, A. M., & McDonnell, S. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-008-9169-z · Cited by 80
Proia, D. A., Zhang, C., Sequeira, M., Jimenez, J.-P., He, S., Spector, N. L., Shapiro, G. I., Tolaney, S. M., Nagai, M., Acquaviva, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2166 · Cited by 69
Guthrie, J. L., Seah, C., Brown, S., et al. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01551-08 · Cited by 68
Galectin-3 expression alters adhesion, motility and invasion in a lung cell line (DLKP), in vitro.
O’Driscoll, L., Linehan, R., Liang, Y. H., Joyce, H., Oglesby, I. K., & CLYNES, M. M. (2002) · PubMed · Cited by 66
Self-citationPerotti, C., Liu, R., Parusel, C. T., Boecher, N., Schultz, J., Bork, P., Pfitzner, E., Groner, B., & Shemanko, C. S. (2008) · Breast Cancer Research · doi:10.1186/bcr2193 · Cited by 55
Loss of Heterozygosity of 14q32 in Colorectal Carcinoma
Bando, T., Kato, Y., Ihara, Y., Yamagishi, F., Tsukada, K., & Isobe, M. (1999) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(98)00242-8 · Cited by 50
Significance of PELP1 in ER-Negative Breast Cancer Metastasis
Roy, S. S., Chakravarty, D., Cortez, V. A., Mukhopadhyay, K. D., Bandyopadhyay, A. M., Ahn, J., Raj, G. V., TEKMAL, R. R., Sun, L., & Vadlamudi, R. K. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0456 · Cited by 43
Standard of Care and Promising New Agents for Triple Negative Metastatic Breast Cancer
Mancini, P., Angeloni, A., Risi, E., Orsi, E., & Mezi, S. (2014) · Cancers · doi:10.3390/cancers6042187 · Cited by 35
Cited by
Maacha, S., Bhat, A. A., Jimenez, L., Raza, A., Haris, M., Uddin, S., & Grivel, J.-C. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0965-7 · Cited by 572
The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors
Izci, M., Maksoudian, C., Manshian, B. B., & Soenen, S. J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00779 · Cited by 506
Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine
Fais, S., O’Driscoll, L., Borras, F. E., Buzas, E., Camussi, G., Cappello, F., Carvalho, J., Cordeiro da Silva, A., Del Portillo, H., El Andaloussi, S., et al. (2016) · ACS Nano · doi:10.1021/acsnano.5b08015 · Cited by 481
Self-citationExosomes as therapeutics: The implications of molecular composition and exosomal heterogeneity
Ferguson, S. W., & Nguyen, J. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.02.037 · Cited by 416
Roles and mechanisms of exosomal non-coding RNAs in human health and diseases
Li, C., Ni, Y.-Q., Xu, H., Xiang, Q.-Y., Zhao, Y., Zhan, J.-K., He, J.-Y., Li, S., & Liu, Y.-S. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00779-x · Cited by 406
Metadata
- Authors
- O’Brien, K., Lowry, M. C., Corcoran, C., Martinez, V. G., Daly, M., Rani, S., Gallagher, W. M., Radomski, M. W., MacLeod, R. A. F., & O’Driscoll, L.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-09-24
- Volume
- 6
- Issue
- 32
- Pages
- 32774-32789
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2194138253
- Cited by
- 273
- References
- 55
- FWCI
- 7.85
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.